Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Topics Community

Article

PD-L1 expression and its relationship with oncogenic drivers in non-small cell lung cancer (NSCLC).

Oncotarget - 18 Apr 2017

Jiang Liyan, Su Xinying, Zhang Tianwei, Yin Xiaolu, Zhang Meizhuo, Fu Haihua, Han Hulin, Sun Yun, Dong Lili, Qian Jialin, Xu Yanhua, Fu Xuan, Gavine Paul R, Zhou Yanbin, Tian Kun, Huang Jiaqi, Shen Dong, Jiang Haiyi, Yao Yihong, Han Baohui, Gu Yi

Abstract excerpt

In order to explore the potential patient population who could benefit from anti PD-1/PD-L1 mono or combination therapies, this study aimed to profile a panel of immunotherapy related biomarkers (PD-1, PD-L1, CTLA-4 and CD8) and targeted therapy biomarkers (EGFR, KRAS, ALK, ROS1 and MET) in NSCLC.Tumor samples from 297 NSCLC patients, including 156 adenocarcinomas (AD) and 129 squamous cell carcinomas (SCC), were...

Topics

Aged
Aged, 80 and over
B7-H1 Antigen
Biomarkers, Tumor
CTLA-4 Antigen
Carcinoma, Non-Small-Cell Lung
Cell Transformation, Neoplastic
Female
Gene Amplification

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Gene Expression

Humans

Immunohistochemistry

In Situ Hybridization, Fluorescence

Lung Neoplasms

Lymphocytes, Tumor-Infiltrating

Male

Middle Aged

Mutation

Source

Open in PubMed Open full text

Identifiers

PMID: 28460468
DOI: 10.18632/oncotarget.15839
PMCID: PMC5432301

Genes

ALK
EGFR
KRAS
MET
ROS1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PD-L1 expression and its relationship with oncogenic drivers in non-small cell lung cancer (NSCLC).PMID 28460468Read ↗

Current Immunotherapeutic Strategies Targeting the PD-1/PD-L1 Axis in Non-Small Cell Lung Cancer with Oncogenic Driver Mutations.Semantic proximity Read ↗

Anti-PD1/PD-L1 Immunotherapy for Non-Small Cell Lung Cancer with Actionable Oncogenic Driver Mutations.Semantic proximity Read ↗

Who Will Benefit Most From PD-L1 Detection and Immunotherapy in Non-small Cell Lung Cancer?Semantic proximity Read ↗

Clinicopathological and molecular characteristics associated with PD-L1 expression in non-small cell lung cancer: a large-scale, multi-center, real-world study in China.Semantic proximity Read ↗

Association of PD-L1 expression with driver gene mutations and clinicopathological characteristics in non-small cell lung cancer: A real-world study of 10 441 patients.Semantic proximity Read ↗

Landscape of Genomic Alterations and PD-L1 Expression in Early-Stage Non-Small-Cell Lung Cancer (NSCLC)-A Single Center, Retrospective Observational Study.Semantic proximity Read ↗

Massive PD-L1 and CD8 double positive TILs characterize an immunosuppressive microenvironment with high mutational burden in lung cancer.Semantic proximity Read ↗

Optimal Management of Patients with Advanced NSCLC Harboring High PD-L1 Expression and Driver Mutations.Semantic proximity Read ↗

Profiling non-small cell lung cancer reveals that PD-L1 is associated with wild type EGFR and vascular invasion, and immunohistochemistry quantification of PD-L1 correlates weakly with RT-qPCR.Semantic proximity Read ↗

Clinical implications of PD-L1 expression in oncogene-driven NSCLC: Differential responses to targeted agents and immune checkpoint inhibitors.Semantic proximity Read ↗

Comprehensive assessment of PD-L1 expression, tumor mutational burden and oncogenic driver alterations in non-small cell lung cancer patients treated with immune checkpoint inhibitorsSemantic proximity Read ↗

Revisiting Biomarker-Guided Therapy in EGFR-Mutant Non-Small Cell Lung Cancer with High PD-L1 Expression.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.